Lupin Grants US Rights For Bioadhesive Technology For Rifaximin To Salix
Lupin has granted Salix Pharmaceuticals the exclusive US rights for its bioadhesive drug delivery technology for use with Rifaximin. Lupin and Salix have entered into an agreement under
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.